Retinitis pigmentosa (RP) is a rare genetic disease that affects 1 in 4000 people worldwide. It is characterized by the progressive loss of photoreceptor cells in the retina, leading to blindness. Protein therapeutics have the potential to slow the progression of RP; however, it is challenging to deliver them to the retina and maintain their bioavailability. My project focuses on utilizing protein-protein interactions to sustain the release of protein therapeutics from a hydrogel drug delivery system to reduce vision loss in patients affected by RP.
PhD Candidate, 2018 - Present